HB 90 (2021): allowing alternative treatment centers to acquire and use in manufacturing hemp-derived cannabidiol (CBD) isolate.
Cite this page
Granite Record indexes the General Court’s record; it is not that record. Where a citation allows only one source, cite the General Court — every page here links to what it is drawn from. The date below is the day the page was read.
- MLA
- “HB 90 (2021): allowing alternative treatment centers to acquire and use in manufacturing hemp-derived cannabidiol (CBD) isolate.” Granite Record, https://graniterecord.org/bill/2021/hb90. Accessed 24 Oct. 2026.
- APA
- Granite Record. (n.d.). HB 90 (2021): allowing alternative treatment centers to acquire and use in manufacturing hemp-derived cannabidiol (CBD) isolate. Retrieved 24 Oct. 2026, from https://graniterecord.org/bill/2021/hb90
- Chicago
- Granite Record. “HB 90 (2021): allowing alternative treatment centers to acquire and use in manufacturing hemp-derived cannabidiol (CBD) isolate.” Accessed 24 Oct. 2026. https://graniterecord.org/bill/2021/hb90.
- BibTeX
@misc{bill-2021-hb90, title = {HB 90 (2021): allowing alternative treatment centers to acquire and use in manufacturing hemp-derived cannabidiol (CBD) isolate.}, howpublished = {Granite Record}, url = {https://graniterecord.org/bill/2021/hb90}, note = {Accessed 24 Oct. 2026} }
HB 90 (2021)
allowing alternative treatment centers to acquire and use in manufacturing hemp-derived cannabidiol (CBD) isolate.
- Status: Killed
- Term: 2021-2022
- House committee: Health, Human Services and Elderly Affairs
- Subject: Public and Mental Health
The Story
It was introduced on January 6, 2021 and referred to the House Health, Human Services and Elderly Affairs committee. The committee voted unanimously, 20–0, to recommend that the House kill it, and the report was placed on the consent calendar. On April 7, 2021 the House voted to kill it on a voice vote. On April 7, 2021 the House failed “Reconsider” on a voice vote, on a motion by Rep. Jason Osborne.
Sponsors
- Rep. Suzanne Vail (D - Hills 30) (prime sponsor)
- Rep. Larry Laflamme (D - Coos 3)
Hearings and Sessions
- February 23, 2021, 9:45 AM: public hearing, House Health, Human Services and Elderly Affairs
Votes
- April 7, 2021, House: Inexpedient to Legislate — voice vote, passed
- April 7, 2021, House: Reconsider — voice vote, failed
The Docket
- January 6, 2021: Introduced (in recess of) 01/06/2021 and referred to Health, Human Services and Elderly Affairs
- February 23, 2021: Public Hearing: 02/23/2021 09:45 am Members of the public may attend using the following link: To join the webinar: https://www.zoom.us/j/95885653389 / Executive session on pending legislation may be held throughout the day (time permitting) from the time the committee is initially convened
- March 2, 2021: Committee Report: Inexpedient to Legislate (Vote 20-0; CC)
- April 7, 2021: Inexpedient to Legislate: MA VV 04/07/2021
- April 7, 2021: Reconsider (Rep. Osborne): MF VV 04/07/2021
Laws It Would Change
Related Bills
- HB 1424 (2020): allowing alternative treatment centers to acquire and use in manufacturing hemp-derived cannabidiol (CBD) isolate.
- HB 1424 (2020): allowing alternative treatment centers to acquire and use in manufacturing hemp-derived cannabidiol (CBD) isolate.